|Bid||7,905.00 x 0|
|Ask||7,905.00 x 0|
|Day's Range||7,842.82 - 7,918.44|
|52 Week Range||71.46 - 10,120.00|
|Beta (5Y Monthly)||0.21|
|PE Ratio (TTM)||36.72|
|Earnings Date||Jul 29, 2021|
|Forward Dividend & Yield||2.07 (2.63%)|
|Ex-Dividend Date||Feb 25, 2021|
|1y Target Est||78.83|
The head of the World Health Organization called on COVID-19 vaccine manufacturers to make shots available to the COVAX vaccine-sharing facility earlier than planned due to a supply shortfall left by Indian export disruptions. COVAX, which supplies doses to poorer countries, relies heavily on India's Serum Institute's exports of the AstraZeneca shot but many of these are instead being used by the country as it battles a massive second wave of infections. The head of UNICEF on Monday asked wealthy G7 countries ahead of a summit next month to donate supplies as an emergency measure to make up the shortfall estimated at 140 million doses by end-May.
AstraZeneca plc (NASDAQ: AZN) presented detailed data from the DARE-19 Phase 3 trial at the American College of Cardiology, evaluating Farxiga (dapagliflozin) to treat hospitalized COVID-19 patients who are at risk of developing serious complications. The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status at 30 days. The Phase 3 trial had enrolled 1,250 hospitalized pandemic patients with underlying conditions. For 30 days, patients were treated daily with either a placebo or dapagliflozin, and they continued that routine regardless of disease progression. Researchers found that 11.2% of dapagliflozin patients died or suffered organ failure - one of the study’s primary endpoints, compared with 13.8% of placebo patients. During the study follow-up, 6.6% of patients in the dapagliflozin group died versus 8.6% in the placebo group. The secondary endpoint of recovery, mostly measured as time to hospital discharge, was similar between the two groups. Despite the failure, it was observed that patients on Farxiga posted numerically fewer serious side effects than placebo in DARE-19 with two non-severe cases of diabetic ketoacidosis observed, both in the Farxiga arm and in patients with prior history of Type 2 diabetes. In the Farxiga arm, there were 21 reports of kidney injury compared with 34 in the placebo group. Meanwhile, there were two reports of ketoacidosis among the Farxiga group compared with none in the placebo arm. See the ACC presentation here. Price Action: AZN shares are trading 0.40% higher at $55.43 during the premarket session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaUK Study Answers Question If Two Doses Of COVID-19 Vaccines Can Be Mix-Matched?UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AstraZeneca stock has yo-yoed as challenges mount for its coronavirus vaccine. But the company's 2021 guidance, raised in April, doesn't count on the Covid vaccine. Is AZN stock a buy?